Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
publication

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?


Wei, A.H. et al.
Cancer Discovery (2019)
Abstract

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias..



Authors

Wei, A.H., Roberts, A.W.



VIEW

publication
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
Albertí-Servera, L.
Blood (2020)
publication
Clonal independence of JAK2 and CALR or MPL mutations in co-mutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing.
Thompson, E.R.
Haematologica (2020)
publication
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
Taylor, J.
Blood (2020)
publication
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Maia, C.
Blood (2020)
REQUEST QUOTE